Objective. Type B fibroblastic synoviocytes are abundant in inflamed joints of patients with rheumatoid arthritis (RA), and can secrete cytokines and other mediators of inflammation. The aim of this study was to determine whether cell lines derived from RA type B synoviocytes could also serve as accessory cells for T lymphocyte activation.
Monoclonal antibodies against IFN y, interleukin-IS (IL-lB, IL-6, IL-8, and tumor necrosis factor a failed to block the T cell proliferative responses, but anti-IL-2 was strongly inhibitory.
Conclusion. Cultured RA type B synoviocytes can perform some of the functions of professional antigen-presenting cells. If such cells have similar properties in vivo, they may be important partkipants in activation of immune responses, in addition to their previously described synthetic and proinflammatory roles. If RA synovial tissue T cells, like normal peripheral blood T cells, can respond to superantigens presented by synoviocytes, this interaction could be important in the pathogenesis of RA.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by proliferation of synoviocytes, persistent inflammation of the synovium, and tissue destruction. Synovial tissue contains at least 2 distinct populations of cells, which have been termed macrophage-like (type A) and fibroblast-like (type B) synoviocytes (1). Local proliferation of type B synoviocytes contributes substantially to the synovial hyperplasia that is characteristic of RA (2). Synthetic functions of type B synoviocytes, including secretion of hyaluronic acid and collagen, have been well documented (3). These cells also contribute to inflammatory responses, by releasing substances such as prostaglandins, metalloproteinases, and cytokines, which regulate cellular function within the synovial compartment and cause tissue damage. These processes are regulated by a variety of cytokines and cytokine inhibitors, acting individually, synergistically, or antagonistically (4-1 l), as well as by mediators of inflammation, such as kinins (12) .
Although some functions of synoviocytes are mediated by secreted products, other functions may require direct interaction with cells of the immune system that migrate to the synovium during inflammation. In order to support antigen presentation to CD4+ T cells, accessory cells must express major histocompatibility complex (MHC) class 11 molecules as well as other, costimulatory molecules. In several reports, type B synoviocytes from patients with RA have been shown to express MHC class 11 , intercellular adhesion molecule 1 (ICAM-1) (CD54), vascular cell adhesion molecule I (VCAM-1) (CDlM), integrins, and other molecules involved in cell-cell interaction within the inflamed joint or ex vivo (4, [13] [14] [15] [16] [17] [18] [19] [20] [21] . MHC class I1 determinants are induced on cultured type B synoviocytes from RA patients in the presence of interferon-y (IFNy) (4). In addition, I F N y and other cytokines have been reported to enhance ICAM-1 and VCAM-1 expression (16, 18, 19) . Anti-VCAM-1 antibodies have been found to block the binding of the Jurkat T cell line to type B synoviocytes (16) .
Despite 
MATERIALS AND METHODS
Monoclonal antibodies. Monoclonal antibodies (MAb), MHC class 11, CD2, CD4, CDlla (lymphocyte functio*associated antigen 1 [LFA-I]), CDl lb (MO-l), CD14 (MO-2), CD50 (ICAM-3), CD54 (ICAM-I), CD58 (LFA-3), CD60, CD8O (B7-1/BBl), CD86, (B7-2, B70), CD98, CD102 (ICAM-2), CD106 (VCAM-l), 54-81 (ALCAM) IFNy, IL-lp, IL-2, IL-6, IL-8, and tumor necrosis factor a (TNFa), as well as isotype-matched control reagents, were used. The anti-CD14 and anti-CD16 MAb were generously provided by Dr. Rob Todd (University of Michigan). Antibodies to ICAM-1 and VCAM-1 were gifts from Dr. Yoji Shimizu (University of Michigan). Antibodies to ICAM-2 and ICAM-3, and the 54-81 antibody were obtained from the Fifth Leukocyte Typing Workshop Blind Panel (25) . Several antibodies were produced as previously described, i.e., anti-CD2 antibody UMCD2 (26) , isotype control anti-von Willebrand factor (27) , and anti-CD98 antibody UM7F8 (28) . Antibody-producing hybridomas, anti-CD58 (TS 2/9.1.4.3.; I s , ) , anti-LFA-la(TS 1/22.1.1.13), and OKT3 (CRL 8001) were purchased from American Type Culture Collection (Rockville, MD). Anti-CD80/B7-1 (Ancell, Bayport, MN), anti-CD86/B7-2/B70 (Pharmigen, San Diego, CA), and neutralizing antibodies to human cytokines IL-1 p, IL-6 (Gibco BRL, Grand Island, NY), IL-2 (R & D Systems, Minneapolis, MN), IL-8, and TNFa (Biosource International, Camarillo, CA) were purchased. A second anti-TNFa MAb termed cA2 (29) and an antibody to IFNy (B133.3.1) were generous gifts from Dr. James Woody (Centodor, Malvern, PA). All reagents were murine monoclonal antibodies except cA2 and B 133.3.1 (chimeric mousehuman monoclonals) and antibodies to IL-1p and IL-6 (rabbit polyclonals). These reagents were used at a final concentration of 10 pg/ml.
For flow cytometric analysis, saturating dilutions of ascites fluid or 10 pg/ml of purified MAb were used. For inhibition of proliferative responses, antibodies were purified by passage over protein A or protein G Sepharose beads and used at a final concentration of 10 pg/ml.
Synoviocyte culture. Synovial specimens obtained at the time of total joint replacement from patients with RA were treated with 4 mg/ml collagenase (type I; Worthington Biochemical, Freehold, NJ) for 4 hours in Dulbecco's modified Eagle's medium (DMEM) at 37°C in 5% C02. The dissociated cells were then centrifuged at SOOg, resuspended in DMEM supplemented with 10% fetal calf serum (FCS; Gibco BRL), 10% human AB serum (Biowhitaker, Walkersville, MD), penicillin (100 units/ml), and streptomycin (100 pg/ml), and plated in 75-cm2 flasks. When the cells reached 95% confluence, they were passaged at a dilution of 1:3 into 175-mm2 flasks. The confluent adherent cells were split by gentle trypsinization (trypsinEDTA; Irvine Scientific, Walkersville, MD). Cells were used between the third and the twelfth passages. IFN y (Genentech, South San Francisco, CArtreated synoviocytes were precultured in 1 ,OOO units/ml IFN y for 48-72 hours before assay.
T lymphocyte purification. Human peripheral blood mononuclear cells (PBMC) from healthy normal donors were separated by Ficoll-Hypaque (Sigma, St. Louis, MO) density gradient centrifugation. T lymphocytes were isolated from the PBMC by separating E+ rosette cells (T cells) and E-rosette cells, using sheep red blood cells. Macrophages were coated with MAb to CD14 and MHC class I1 molecules, and were depleted from the E+ rosette cells by 2 rounds of panning with microselector flasks (Applied Immune Sciences, Santa Clara, CA). Depletion of accessory cells from T lymphocyte preparations was monitored, and confirmed by lack of T cell proliferation with SEA, SEB, and Prolieration assays. SEA and SEB were purchased from Sigma, and phytohemagglutinin (PHA) from Munex Diagnostics (Atlanta, GA). Proliferation assays were performed in triplicate. T cells (5 X 104) purified as described above, were cultured in 96-well round-bottomed culture plates (Costar, Cambridge, MA). Synoviocytes (10'4 x 104) were added to the wells with OKT3, SEA, SEB, and PHA as stated in figure legends, in a final volume of 0.2 ml RPMI 1640 with 10% FCS. Antibodies recognizing synoviocytes and T cells were used at the concentrations indicated. Plates were incubated for 4 days at 37°C with 5% CO,, pulsed for the final 18 hours of culture with 1 pCi/well of 'H-thymidine (ICN Biomedicals, Irvine, CA), harvested, and counted in a liquid scintillation counter (Pharmacia 1205/1204 BS Beta Counter). For proliferation assays, the results shown (mean 5 SD) are from single experiments representative of at least 3 similar experiments, using synoviocytes from different patients and T cells from different normal donors.
Fluorescence-activated cell sorter (FACS) analysis.
Flow cytometric analysis was performed using an Elite cell sorter (Coulter Electronics, Hialeah, FL). Positive cells were defined as those with fluorescence intensity beyond a threshold defined by the negative control (cells stained with isotype-matched nonspecific mouse Ig). Dead cells were excluded from analysis using forward and right-angle light scatter gating. Cell staining was measured in arbitrary units as the log fluorescence intensity and was recorded on a 3-log scale. For indirect immunofluorescence staining, phycoerythrin-conjugated second antibody was used to minimize background autofluorescence of synoviocytes (Molecular Probes, Eugene, OR).
Effects of synoviocyte supernatants. Seventh-passage synoviocytes (5 x 10S/well), both IFNy-treated and nonIFNytreated, were placed in a 24-well plate and stimulated anti-CD3.
with SEA for 12, 18, or 24 hours. The cells were placed at a final volume of 1 ml RPMI and 10% FCS. Aliquots of the supernatants (150 p) were placed in 96-well round-bottomed plates in triplicate, and 5 x lo4 T cells in 50 p.l were added to each well. Assays were performed in triplicate, and proliferation was measured as described above.
RESULTS
Synoviocyte expression of molecules necessary for T cell costimulation. FACS analysis was used to determine which molecules important for T cell co- A, Synoviocytes (5 x 16) were placed in 2Cwell plates and incubated for 4 days. B, Synoviocytes (5.0 x 10') were cocultured with 2.5 x lo6 T lymphocytes for 2 days in 24-well plates. C, Synoviocytes (5.0 x 10') and T lymphocytes (2.5 x 106) were cultured with SEA (100 ng/ml) for 2 days. Wells were washed twice with RPMI 164&10% fetal calf serum pior to photographing. stimulation were found on the surface of synoviocytes and CD14 (MO-2) were found at low levels (results not in culture. CD106 (VCAM-l), CD98, and J4-81/ shown). In contrast, CDSO (B7-BBl), CD86 (B7-2), ALCAM (a putative ligand for CD6), were found at and the MHC class I1 molecule were generally not high densities (Table I) , while CDIlb/CD18 (MO-1) detectable (Table I ). The level of expression of CD54 (ICAM-1) and CD58 (LFA-3) varied according to the extent of passage in vitro. Synoviocytes were treated with 1 ,OOO units/ml of IFNy for 48-72 hours to induce MHC class I1 expression as described by Burmester et a1 (17) . IFN ytreated synoviocytes were screened by FACS to examine whether any additional surface molecules were positively or negatively modulated on these cells. The expression of CD8O (B7-l), CD86 (B7-2), and CD98 did not change with IFNy treatment. The expression of CD54 (ICAM-I), CD58 (LFA-3), CDIM (VCAM-l), and MHC class I1 was significantly upregulated (Table 1 ). CD14 (M02) and CD1 lb/CD18 (M01) were expressed on a subset of cells at passages 4-6, but were undetectable or present on a much smaller number of cells in later passages (data not shown). CD50 (ICAM-3) and CD102 (ICAM-2) were absent or expressed at very low levels, with or without IFN y treatment (data not shown).
SAg promotion of T lymphocyte binding to synoviocytes. We examined whether SAg affects the ability of peripheral blood T lymphocytes to adhere to type B synoviocytes (Figure 1 ). RA type B IFNytreated synoviocytes bound small numbers of peripheral blood T lymphocytes without SEA (Figure 1) . However, when SEA was added, the synoviocytes bound T cells at a much higher density, as measured by phasecontrast microscopy ( Figure 1) . Enumeration of T cells bound per high power field revealed that I F N y treated synoviocytes bound 3.5 times the number of T cells in the presence of SEA compared with binding in the absence of SEA.
Synoviocyte support of the SEA response. To investigate the ability of synoviocytes to support the SEA response, IFN ytreated and non-IFN ytreated synoviocytes were cocultured with highly purified allogeneic resting T cells. Proliferation experiments showed that, in the presence of SEA, synoviocytes induced T cell activation and proliferation (Figure 2a ). The T cell response was SEA dosedependent, with 10 ng/ml or 100 ng/ml SEA stimulating a greater T cell response than 1 ng/ml. The optimal response was found using 5,000 synoviocytes and 50,000 T cells presenting cell population such as synovial monocytes, provided the observed accessory function is supported by several lines of evidence. First, excellent accessory cell function was seen with late-passage cultures (passages 10-12), at which time no monocytes or negligible numbers of monocytes are detectable using flow cytometric analysis of surface markers. Excellent responses were observed with 5,000 cells per well, such that the absolute numbers of contaminating cells would be very low. Furthermore, accessory cell function was actually more potent with later, rather than earlier, passages of the same synoviocyte lines, with an inverse correlation between the percentage of cells with monocyte surface markers present and the strength of the responses to superantigen or lectin upon coculture with T lymphocytes (Diaz L, Fox D: unpublished data). Finally, in most of the experiments, the T cell response to allogeneic synoviocytes was no greater than a few hundred counts per minute above background (occasionally slightly higher, as in Figure 3) , inconsistent with the presence of substantial numbers of professional antigenpresenting cells, which are typically excellent stimulators of allogeneic responses, Poor allostimulatory capacity of mixed synoviocyte populations has been observed previously (30) . The T cell populations used were sufficiently depleted of accessory cell populations such that they could not respond to superantigen or anti-CD3, although partial responses to PHA were sometimes seen (Figure 3) .
Consistent with this evidence for low levels of contamination by professional antigen-presenting cells was the absence of significant levels of MHC class I1 expression on synoviocytes unless these cells were cultured with IFNy. Other published studies have shown that a variety of important cell interaction molecules, including MHC class 11, ICAM-I (CD54), and VCAM-1 (CD106), are inducible on synoviocytes with' IFNy, and such molecules have been detected in vivo and implicated in the pathogenesis of RA (3 1). An interesting finding in the present studies was that IFNy was not necessary for accessory cell function of synoviocytes, although it boosted such function in most experiments. A spectrum of results was obtained, ranging from minimal but clearly detectable accessory cell function in the absence of IFNy (Figure 2a ) to modest augmentation of accessory cell function following treatment with IFNy ( Figure 5 ) to equivalent accessory cell function in the presence and absence of IFN y (Figure 3) .
The observation that synoviocytes can present superantigen in the absence of baseline MHC class I1 expression detectable by flow cytometric analysis suggests several potential explanations. One possibility is that synoviocyte molecules other than MHC class I1 are responsible for presenting superantigen, as has been suggested in other experimental systems (32, 33) . Alternatively, MHC class 11 molecules may be expressed at functionally significant levels by synoviocytes, but at a surface density too low to be detected by flow cytometry. Finally, it is plausible that MHC class I1 is significantly up-regulated on synoviocytes early during coculture with T cells, facilitating presentation of superantigen. In support of either or both of these latter 2 possibilities, antibody against MHC class I1 effectively blocked superantigen presentation (Figure 5) . In other experiments (results not shown), lower concentrations of anti-MHC class I1 more effectively blocked antigen presentation by non-IFN ?pretreated cells compared with IFN ypretreated synoviocytes. These results are consistent with functionally relevant low-level MHC class I1 expression on non-IFNy pretreated synoviocytes. It appears likely that functional assays using blocking effects of antibodies are more sensitive for demonstrating a role of MHC class 11 in these experiments than is baseline flow cytometric staining.
The foregoing considerations suggest that in experiments in which IFN y boosted accessory cell function of synoviocytes, superinduction of expression of MHC class I1 antigens might not necessarily be the principal reason for the observed functional changes. A variety of other accessory cell surface molecules may serve as costimulatory ligands for T cell surface structures in the response to superantigen, as in other T cell responses. The role of specific costimulatory structures in SAg responses may be complex, with distinct effects on transcription and secretion of various T cell cytokines (34) . RA type B synoviocytes express ICAM-1 in vivo, but ICAM-2 and ICAM-3 are expressed only on endothelial cells and leukocytes in synovium (31, 35) . This distinction appears to be maintained in vitro on type B synoviocytes. CD28 ligands are absent on or barely expressed by type B synoviocytes (Table 1 ). The role of these molecules in T cell proliferative responses to SAg is controversial (36) (37) (38) , but interaction of CD28 with its ligands may be involved in SAg-triggered T cell-B cell cooperation (39) .
In order to determine the necessary costimulatory receptors and ligands for T cell responses to SAg presented by synoviocytes, antibodies were used in blocking experiments. When used at high concentrations (10 pg/ml), purified antibodies directed at LFA-1 (CD1 ldCD18) and CD2 strongly inhibited superantigen responses of T lymphocytes in the presence of either IFN ypretreated or untreated synoviocytes. In other experiments (results not shown), lower concentrations of antibody showed more variable inhibitory effects, and inhibition was less effective with IFNy pretreated synoviocytes. Such results are compatible with higher expression of costimulatory ligands for CD2 and LFA-1 on IFNytreated synoviocytes, such that blocking effects of monoclonal antibodies are difficult to obtain at lower antibody concentrations. Consistent with this interpretation was the finding that expression of CD54 and CD58, ligands for LFA-I and CD2, respectively, were up-regulated with IFN y treatment. Even when a majority of cells expressed these molecules at baseline, surface density was increased following exposure to IFN y.
It was noted that anti-CD58 did not block T cell responses despite blocking effects of anti-CD2. This may indicate insufficient affinity of the anti-CD58 reagent, or alternatively, may suggest that anti-CD2 has effects on T cell function other than inhibition of CD58 binding. These could include inhibition of binding to other CD2 ligands or direct regulatory signals generated through CD2. Anti-CD98 antibody did not block T cell proliferation in response to SEA presented by IFN ytreated or non-IFN ytreated synoviocytes. However, it has been demonstrated to block the T cell response to SEA with PBMC acting as antigenpresenting cells (40) . These discrepancies are probably due to differences in the antigen-presenting cell populations used in these 2 systems.
Effects of antibodies directed at cell-cell interaction structures suggest that the observed T cell responses required cell-cell contact, not merely factors secreted by accessory cells. Considerable binding of T cells to synoviocytes was observed, particularly in the presence of superantigen (Figure 1 ). Since superantigen-stimulated synoviocytes have been found to secrete cytokines such as IL-6 and IL-8 (22) , it was important to establish that supernatants of superantigen-treated synoviocytes could not by themselves support T cell proliferation, and this was demonstrated by the data shown in Figure 4 . These data do not, however, exclude an important role for cytokines in costimulating the observed T cell responses, and effects of anticytokine monoclonal antibodies were therefore investigated. Individual antibodies to IFN y, IL-lp, IL-6, IL-8, and TNFa did not down-regulate synoviocyte/SEA-induced T cell proliferation. These results must be interpreted with caution, however. Although the antibodies were selected because of documented neutralizing properties (refs. 41 and 42, and manufacturers' data), massive antibody concentrations might be needed to block the responses examined in this study. If membrane-bound cytokines play a role in regions of close cell contact, antibody blocking might be inefficient. Further studies using combinations of antibodies seem warranted. A blocking antibody directed at human IL-2 did inhibit T cell proliferation significantly, consistent with an IL-2/IL-2 receptor-dependent T cell activation pathway triggered by superantigen presented by synoviocytes.
Although type B fibroblastic synoviocytes were potent accessory cells for T cell responses to superantigen and lectin, such cells may not exhibit a full spectrum of accessory cell functions. Thus, responses to anti-CD3 antibody were not well supported by synoviocyres, possibly relating to poor expression of Fc receptors on these cells or a requirement for CD28 ligands on accessory cells for this response. A recent study has suggested that synoviocytes can play a role in autologous presentation to T cells of a nominal antigen, tetanus toxoid, which is MHC class I1 restricted (43). Furthermore, synoviocytes were able to function as antigen-presenting cells for T cell clones specific for mycobacterial antigens, also in an MHC class 11-restricted system (43) . However, the proliferative responses observed were relatively modest. In contrast, strong proliferative responses were observed in the present studies with low SAg concentrations, comparable with SAg responses supported by professional antigen-presenting cells, and in contrast to responses supported by the murine fibroblast L cell line transfected with MHC class I1 molecules, which require much higher SAg concentrations (37) .
Synoviocytes are not necessarily the only type of fibroblastic cell capable of functioning in antigen presentation. A recent report documents the capacity of fibroblasts transfected with viral proteins to induce antiviral cytotoxic T lymphocyte responses independent of other professional antigen-presenting cells, but only in the environment of lymphoid organs (44) . In this regard, our findings with RA type B synoviocytes could be relevant to cell-cell interactions in vivo, given the histologic resemblance of RA synovial inflammation to lymphoid tissue in patients with active disease.
A role for superantigens in the pathogenesis of RA would depend on the functional properties of accessory cells found in the synovium (and possibly elsewhere) and on the responses of T lymphocytes to such antigens. Some recent reports have suggested that the V p repertoire in RA reflects SAg responses (23, 24) , but other studies have yielded somewhat contradictory results (45, 46) . No reports, to our knowledge, have documented the ability of synovial tissue cells to present SAg to T lymphocytes.
Superantigens have been implicated in various infectious diseases due to staphylococci and mycobacteria (47, 48) . Endogenous superantigens have been identified in mice (for review, see ref. 49) but not yet in humans. In animal models, SAg responses can initiate joint inflammation (50) or exacerbate autoimmune responses in the synovium (51) or in the central nervous system (52, 53) . If SAg have a role in autoimmune diseases with organ-specific manifestations, SAg presentation by cells localized to such organs could be important. Pertinent findings in this regard include the recent demonstration that keratinocytes can present SAg in an LFA-l/ICAM-Mependent manner (5435) and a report of SAg presentation by intestinal epithelial cells (56) . Dendritic cells localized to the skin (57), the joint (58), or other tissues could also be important in localized SAg presentation. Recently, evidence for a SAg effect on lymphocytes infiltrating the pancreas in early type I diabetes has been described (59) .
The data in this report demonstrate that cultured rheumatoid type B fibroblast-like synoviocytes are capable of supporting T lymphocyte proliferation in response to SAg and lectin. This system, while not establishing a role for SAg in RA, provides a new and useful model for examining synoviocyte-T cell interactions in induction of T cell responses that could contribute to the pathogenesis of this disease. These findings, together with evidence that RA type B synoviocytes can support differentiation of B cells into plasma cells (60) , begin to define a role for synoviocytes in the induction of immune responses. 
